Portfolio company
Intercept Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops and commercialises small molecule therapeutics to treat chronic liver diseases for healthcare providers and patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Inventiva
This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.
Cymabay Therapeutics
This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.
Metabolys
This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.
Akero Therapeutics
This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.
Eternygen
This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.
Pharmacyclics
This company develops small-molecule medicines for patients with cancer and immune-mediated diseases.
Enanta
This biotechnology company develops small molecule medicines to treat viral infections and immunological diseases for patients with serious medical conditions.
SFA Theraputics
This biopharmaceutical company develops oral small-molecule drugs for patients suffering from autoimmune diseases, chronic inflammatory conditions, and various types of liver cancer.